FDA Plans ODAC Review, Delays PDUFA Date for Idecabtagene Vicleucel
- Bristol Myers Squibb and 2seventy bio, Inc. today announced the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) will meet to review data supporting the supplemental Biologics License Application (sBLA) for Abecma (idecabtagene vicleucel) for earlier lines of triple-class exposed relapsed or refractory multiple myeloma (RRMM) based on results from the pivotal Phase 3 KarMMa-3 study.
- The date of the ODAC meeting has not yet been confirmed by the FDA.
- The FDA also informed the companies that a decision on the application will not be made by the Prescription Drug User Fee Act (PDUFA) target action date of December 16, 2023.
Share:
More News
Dr Jonathan Kwok, Chief Executive Officer & Co-Founder at Infinitopes, commented: “We are delighted that we have advanced our lead vaccine candidate, ITOP1, from university research to a groundbreaking clinical programme in just over three years. This marks a major performance milestone for the company, bringing Infinitopes an important step
“Of note, our team has been simultaneously progressing our Phase 1 AML trial in the U.S. Their incredible efforts cannot be under-emphasized, and I wish to convey my gratitude to our extremely competent and efficient team. We are looking forward to sharing progress on each of our two Phase 1
“CVHNLC is our second oncology program to enter the clinical stage, highlighting the continued progress we are making with our mRNA-based precision immunotherapies. Importantly, we have been able to design CVHNLC using both known, shared tumor antigens and novel proprietary antigens discovered using our differentiated in-house technology platform,” said Dr.
“Treating metastatic HR positive, HER2 negative breast cancer presents challenges, particularly treatment resistance and disease progression that occur following endocrine-based therapy and initial chemotherapy,” said Ken Keller, Global Head of Oncology Business, and President and CEO, Daiichi Sankyo, Inc. “DATROWAY represents the second antibody drug conjugate approved for breast cancer
